Current status and future of relapsed primary central nervous system lymphoma (PCNSL). [electronic resource]
Producer: 20031205Description: 627-33 p. digitalISSN:- 1042-8194
- Adult
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antimetabolites, Antineoplastic -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Agents, Alkylating -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin -- therapeutic use
- Central Nervous System Neoplasms -- mortality
- Cyclophosphamide -- therapeutic use
- Disease-Free Survival
- Etoposide -- analogs & derivatives
- Female
- Humans
- Lymphoma -- mortality
- Male
- Methotrexate -- therapeutic use
- Middle Aged
- Organophosphorus Compounds -- therapeutic use
- Radioimmunotherapy -- methods
- Recurrence
- Rituximab
- Time Factors
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.